{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:45:40Z","timestamp":1771472740662,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd008011.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T00:00:00Z","timestamp":1471910400000}}],"reference-count":74,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008011.pub3","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T14:48:51Z","timestamp":1471963731000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer"],"prefix":"10.1002","volume":"2016","author":[{"given":"Daniel KL","family":"Cheuk","sequence":"first","affiliation":[{"name":"The University of Hong Kong, Queen Mary Hospital; Department of Pediatrics and Adolescent Medicine; Pokfulam Road Hong Kong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elske","family":"Sieswerda","sequence":"additional","affiliation":[{"name":"Emma Children's Hospital\/Academic Medical Center; Department of Paediatric Oncology; PO Box 22660 Amsterdam Netherlands 1100 DD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira C","family":"van Dalen","sequence":"additional","affiliation":[{"name":"Emma Children's Hospital\/Academic Medical Center; Department of Paediatric Oncology; PO Box 22660 Amsterdam Netherlands 1100 DD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleida","family":"Postma","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen and University of Groningen, Beatrix Children's Hospital; Department of Paediatric Oncology; Postbus 30.000 Groningen Netherlands 9700 RB"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leontien CM","family":"Kremer","sequence":"additional","affiliation":[{"name":"Emma Children's Hospital\/Academic Medical Center; Department of Paediatric Oncology; PO Box 22660 Amsterdam Netherlands 1100 DD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,23]]},"reference":[{"issue":"19","key":"10.1002\/14651858.CD008011.pub3-BIB0001|cit1","first-page":"1503-5, 510","article-title":"Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children","volume":"15","author":"Chen","year":"2008","journal-title":"Chinese Journal of Cancer Prevention and Treatment"},{"issue":"2","key":"10.1002\/14651858.CD008011.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/biostatistics\/5.2.263","article-title":"Optimal multivariate matching before randomization","volume":"5","author":"Greevy","year":"2004","journal-title":"Biostatistics"},{"issue":"465","key":"10.1002\/14651858.CD008011.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1198\/016214504000000025","article-title":"Randomization inference with imperfect compliance in the ACE-inhibitor after anthracycline randomized trial","volume":"99","author":"Greevy","year":"2004","journal-title":"Journal of the American Statistical Association"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0006|cit4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ppedcard.2004.12.005","article-title":"Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE-inhibitor after anthracycline trial","volume":"20","author":"Silber","year":"2005","journal-title":"Progress in Pediatric Cardiology"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0007|cit5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/pbc.20351","article-title":"The role of afterload reduction in the prevention of late anthracycline cardiomyopathy","volume":"44","author":"Silber","year":"2005","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0004|cit6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1067\/mhj.2001.118115","article-title":"Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors","volume":"142","author":"Silber","year":"2001","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD008011.pub3-BIB0005|cit7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2004.06.022","article-title":"Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines","volume":"22","author":"Silber","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijcard.2006.07.051","article-title":"Levosimendan in acute decompensation of anthracycline-induced cardiotoxicity","volume":"118","author":"Garcia","year":"2007","journal-title":"International Journal of Cardiology"},{"issue":"15","key":"10.1002\/14651858.CD008011.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.2004.01.047","article-title":"Using health-related quality of life measures to predict cardiac function in survivors exposed to anthracyclines","volume":"22","author":"Ginsberg","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD008011.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/jama.298.10.1171","article-title":"Carvedilol for children and adolescents with heart failure: a randomized controlled trial","volume":"298","author":"Shaddy","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD008011.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1067\/mhj.2002.124402","article-title":"The pediatric randomized carvedilol trial in children with heart failure: rationale and design","volume":"144","author":"Shaddy","year":"2002","journal-title":"American Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD008011.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.healun.2004.12.108","article-title":"Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure","volume":"24","author":"Tallaj","year":"2005","journal-title":"Journal of Heart and Lung Transplantation"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0013|cit13","first-page":"106","article-title":"Effect of propranolol in silent myocardial ischemia induced by anthracyclines","volume":"1","author":"Vatutin","year":"2001","journal-title":"Likars'ka sprava"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0014|cit14","unstructured":"Mandric CG Miron I Dimitriu AG Baghiu D Dimitriu L Miron OT The utility of enalapril treatment in anthracyclines-induced cardiac injury in children with malignancies - preliminary study Proceedings of the 40th Annual Conference of International Society of Paediatric Oncology (SIOP); 2008 Oct 2-6; Berlin, Germany 2008 Abstract L.030, print: 207-8"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Mandric CG Miron I Dimitriu AG Dumitriu IL Cardiac biomarkers in early detection of cardiotoxicity anthracycline-induced in children Proceedings of the 41st Annual Conference of International Society of Paediatric Oncology (SIOP); 2009 Oct 5-9; Sao Paulo, Brazil 2009 Abstract PQ.020, Pediatric Blood & Cancer 2009;53:858","DOI":"10.1002\/pbc.22234"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0016|cit16","unstructured":"NCT00003070 Afterload reduction therapy for late anthracycline cardiotoxicity: a Pediatric Oncology Group Cancer Control Study http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=NCT00003070. Accessed on 29 September 2015"},{"issue":"1","key":"10.1002\/14651858.CD008011.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejheart.2005.03.006","article-title":"Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction - a meta-analysis","volume":"8","author":"Abdulla","year":"2006","journal-title":"European Journal of Heart Failure"},{"issue":"24","key":"10.1002\/14651858.CD008011.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1158\/1078-0432.CCR-13-3490","article-title":"Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors","volume":"20","author":"Armenian","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD008011.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"16","author":"Armenian","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"23","key":"10.1002\/14651858.CD008011.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD008011.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"9146","key":"10.1002\/14651858.CD008011.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0023|cit23","unstructured":"Children's Oncology Group Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, version 3.0 Arcadia, CA. 2006. Available at: www.survivorshipguidelines.org"},{"issue":"23","key":"10.1002\/14651858.CD008011.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008011.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/CIRCULATIONAHA.106.666016","article-title":"Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial","volume":"116","author":"Colucci","year":"2007","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD008011.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0735-1097(98)00675-5","article-title":"Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction","volume":"33","author":"Exner","year":"1999","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD008011.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.287.7.883","article-title":"Beta-blocker therapy in heart failure: scientific review","volume":"287","author":"Foody","year":"2002","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD008011.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.echo.2007.04.007","article-title":"Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients","volume":"20","author":"Ganame","year":"2007","journal-title":"Journal of the American Society of Echocardiography"},{"issue":"18","key":"10.1002\/14651858.CD008011.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD008011.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1071-9164(05)80006-5","article-title":"Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial","volume":"1","author":"Glick","year":"1995","journal-title":"Journal of Cardiac Failure"},{"issue":"9386","key":"10.1002\/14651858.CD008011.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0032|cit32","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"issue":"8997","key":"10.1002\/14651858.CD008011.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0140-6736(96)90469-9","article-title":"Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy","volume":"347","author":"Jensen","year":"1996","journal-title":"The Lancet"},{"issue":"5","key":"10.1002\/14651858.CD008011.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/annonc\/mdf132","article-title":"Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients","volume":"13","author":"Jensen","year":"2002","journal-title":"Annals of Oncology"},{"issue":"9372","key":"10.1002\/14651858.CD008011.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(03)13501-5","article-title":"Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study","volume":"361","author":"Jong","year":"2003","journal-title":"The Lancet"},{"issue":"5","key":"10.1002\/14651858.CD008011.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1067\/mhj.2001.119423","article-title":"Congestive heart failure in pediatric patients","volume":"142","author":"Kay","year":"2001","journal-title":"American Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD008011.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/annonc\/mdf167","article-title":"Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review","volume":"13","author":"Kremer","year":"2002","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD008011.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","article-title":"A clinicopathologic analysis of adriamycin cardiotoxicity","volume":"32","author":"Lefrak","year":"1973","journal-title":"Cancer"},{"issue":"12","key":"10.1002\/14651858.CD008011.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"The New England Journal of Medicine"},{"issue":"23","key":"10.1002\/14651858.CD008011.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2002.12.102","article-title":"Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer","volume":"20","author":"Lipshultz","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD008011.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","article-title":"Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia","volume":"23","author":"Lipshultz","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1542\/peds.2004-1004","article-title":"Cardiac changes associated with growth hormone therapy among children treated with anthracyclines","volume":"115","author":"Lipshultz","year":"2005","journal-title":"Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD008011.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","article-title":"Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors","volume":"40","author":"Maggioni","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"issue":"9386","key":"10.1002\/14651858.CD008011.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"The Lancet"},{"issue":"3","key":"10.1002\/14651858.CD008011.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/jpet.113.204057","article-title":"Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs","volume":"346","author":"Minotti","year":"2013","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0046|cit46","unstructured":"Kremer LCM van Dalen EC Moher D Caron HN. Childhood Cancer Group About the Cochrane Collaboration (Cochrane Review Groups CRGs) 2008, Issue 4 Art. No.: CHILDCA"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD008011.pub3-BIB0048|cit48","first-page":"115","article-title":"Beta-blockade in adriamycin-induced cardiomyopathy","volume":"6","author":"Noori","year":"2000","journal-title":"Journal of Cardiac Failure"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0049|cit49","volume-title":"Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels","author":"The Criteria Committee of the New York Heart Association","year":"1994"},{"issue":"21","key":"10.1002\/14651858.CD008011.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD008011.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/01.CIR.94.11.2793","article-title":"Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise","volume":"94","author":"Packer","year":"1996","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0053|cit53","unstructured":"The Nordic Cochrane Centre. The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"2","key":"10.1002\/14651858.CD008011.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0735-1097(94)90426-X","article-title":"Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction","volume":"23","author":"Rogers","year":"1994","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD008011.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/annonc\/mdr595","article-title":"The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors","volume":"23","author":"Sieswerda","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0056|cit56","unstructured":"Scottish Intercollegiate Guideline Network (SIGN) Long-term follow up care of survivors of childhood cancer 2013. SIGN publication no. 132: available at: http:\/\/www.sign.ac.uk\/pdf\/sign132.pdf. Accessed on 8 August 2016."},{"key":"10.1002\/14651858.CD008011.pub3-BIB0057|cit57","unstructured":"Skinner R Wallace WH Levitt G Therapy based long term follow up: A practice statement (second edition) United Kingdom Children's Cancer Study Group, Late Effects Group"},{"issue":"5","key":"10.1002\/14651858.CD008011.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators","volume":"325","year":"1991","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008011.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators","volume":"327","year":"1992","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD008011.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/cncr.11274","article-title":"Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study","volume":"97","author":"Sorensen","year":"2003","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1542\/peds.89.5.942","article-title":"Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the Children's Cancer Study Group","volume":"89","author":"Steinherz","year":"1992","journal-title":"Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD008011.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/mpo.2950240604","article-title":"Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients","volume":"24","author":"Steinherz","year":"1995","journal-title":"Medical and Pediatric Oncology"},{"issue":"3","key":"10.1002\/14651858.CD008011.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cardfail.2013.12.018","article-title":"Cancer therapy-induced left ventricular dysfunction: interventions and prognosis","volume":"20","author":"Thakur","year":"2014","journal-title":"Journal of Cardiac Failure"},{"issue":"17","key":"10.1002\/14651858.CD008011.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.2003.99.006","article-title":"Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence","volume":"21","author":"Dalen","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"10.1002\/14651858.CD008011.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.ejca.2006.08.005","article-title":"Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study","volume":"42","author":"Dalen","year":"2006","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD008011.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1016\/j.ejca.2006.08.002","article-title":"Anthracycline-induced cardiotoxicity: Comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials","volume":"42","author":"Dalen","year":"2006","journal-title":"European Journal of Cancer"},{"issue":"9","key":"10.1002\/14651858.CD008011.pub3-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006647.pub4","article-title":"Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer","author":"Dalen","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"13","key":"10.1002\/14651858.CD008011.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2010.33.4730","article-title":"High risk of symptomatic cardiac events in childhood cancer survivors","volume":"30","author":"Pal","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD008011.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0002-9343(77)90315-1","article-title":"Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases","volume":"62","author":"Hoff","year":"1977","journal-title":"American Journal of Medicine"},{"issue":"8885","key":"10.1002\/14651858.CD008011.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/0140-6736(93)92930-R","article-title":"Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group","volume":"342","author":"Waagstein","year":"1993","journal-title":"The Lancet"},{"issue":"8","key":"10.1002\/14651858.CD008011.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1161\/01.CIR.0000085166.44904.79","article-title":"Natural history of asymptomatic left ventricular systolic dysfunction in the community","volume":"108","author":"Wang","year":"2003","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD008011.pub3-BIB0072|cit72","first-page":"473","article-title":"Principles and practice of screening for disease","volume":"22","author":"Wilson","year":"1968","journal-title":"WHO Chronicle"},{"issue":"4","key":"10.1002\/14651858.CD008011.pub3-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008011","article-title":"Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer","author":"Sieswerda","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD008011.pub3-BIB0074|cit74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008011.pub2","article-title":"Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer","author":"Sieswerda","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008011.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T03:39:39Z","timestamp":1718854779000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008011.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Childhood Cancer Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,23]]},"references-count":74,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008011.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,23]]}}}